This article was originally published in The Gray Sheet
Reverse 20-for-one stock split will be submitted for shareholder approval at a special meeting scheduled for the week of Feb. 15, 1999. About 58 mil. shares were issued and outstanding as of Nov. 30. St. Paul, Minnesota-based Medtox' "low stock price restricts the company's presence in the equity markets," the firm explains. The AMEX-traded issue is currently trading at around 30 cents a share
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.